SciSparc Ltd. has entered into an exclusive patent license agreement with Polyrizon Ltd. on August 13, 2024, for the out-licensing of its SCI-160 pain therapy program. Under the agreement, Polyrizon will receive exclusive, royalty-bearing global rights to develop and sublicense the assets, while SciSparc will receive Polyrizon securities valued at $3 million and potential milestone fees of approximately $3 million if certain development targets are met.The licensed SCI-160 program is an innovative synthetic combination of cannabinoids and N-acylethanolamines for pain treatment. Pre-clinical studies have shown the treatment to be well-tolerated with comparable or superior analgesic effects to high-dose morphine, without significant adverse effects in both acute and chronic pain conditions.The agreement also includes the termination of a previous co-development agreement dated May 30, 2022, between the two companies. Notably, SciSparc's CEO and CFO Oz Adler serves as a board member of Polyrizon, and the deal structure allows SciSparc to potentially benefit from royalties without additional development investment.

SciSparc Ltd. has entered into an exclusive patent license agreement with Polyrizon Ltd. on August 13, 2024, for the out-licensing of its SCI-160 pain therapy program. Under the agreement, Polyrizon will receive exclusive, royalty-bearing global rights to develop and sublicense the assets, while SciSparc will receive Polyrizon securities valued at $3 million and potential milestone fees of approximately $3 million if certain development targets are met.The licensed SCI-160 program is an innovative synthetic combination of cannabinoids and N-acylethanolamines for pain treatment. Pre-clinical studies have shown the treatment to be well-tolerated with comparable or superior analgesic effects to high-dose morphine, without significant adverse effects in both acute and chronic pain conditions.The agreement also includes the termination of a previous co-development agreement dated May 30, 2022, between the two companies. Notably, SciSparc's CEO and CFO Oz Adler serves as a board member of Polyrizon, and the deal structure allows SciSparc to potentially benefit from royalties without additional development investment.